Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 8/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.64 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.64 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21800673 | 0.89 | PKM (0.74) | PKMALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL21800645 | 0.89 | PKM (0.74) | PKMALDH1A1KMT2APLA2G1BATG4B | |
| SCHEMBL21800632 | 0.89 | PKM (0.84) | PKMALDH1A1KMT2AMEN1PLA2G1B | |
| SCHEMBL21883469 | 0.88 | PKM (1.00) | PKMALDH1A1KMT2AMEN1PLA2G1B | |
| SCHEMBL20509048 | 0.88 | PKM (0.76) | PKMALDH1A1HSD17B10KMT2AMEN1 | |
| SCHEMBL21800677 | 0.87 | PKM (0.88) | PKMALDH1A1KMT2AMEN1PLA2G1B | |
| SCHEMBL21800579 | 0.86 | PKM (0.79) | PKMALDH1A1KMT2AMEN1PLA2G1B | |
| SCHEMBL21800646 | 0.86 | PKM (0.82) | PKMALDH1A1KMT2AMEN1PLA2G1B | |
| SCHEMBL21800652 | 0.86 | PKM (0.86) | PKMALDH1A1KMT2AMEN1PLA2G1B | |
| SCHEMBL21800692 | 0.85 | PKM (0.77) | PKMKMT2AMEN1PLA2G1BATG4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | ETERNYGEN GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | ETERNYGEN GMBH (DE) | 2020-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200087258-A1 | INHIBITOR OF CITRATE TRANSPORTER AND THEIR USE IN THERAPY | CS, SLC2A1, SLC2A2 | PKM 498/4885ALDH1A1 737/4885HSD17B10 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.